Lupin targets GSK's Advair; Drugmakers often violate marketing codes;

@FiercePharma: ICYMI earlier: Pharma's top 10 deals of 2014. Feature | Follow @FiercePharma

@CarlyHFierce: Pharma wanted pricey orphan meds, and now it's got 'em in record numbers. Story | Follow @CarlyHFierce

> Indian drugmaker Lupin is launching a new inhaler in the U.S. while also working on a generic version of GlaxoSmithKline's ($GSK) Advair Diskus. Story

> A study finds that drugmakers often violate voluntary marketing codes in the U.K. and Sweden. Report

> Will Apotex's FDA quality entanglements affect its chances of getting a biosimilar of Amgen's ($AMGN) Neupogen approved in the U.S.? Blog

Medical Device News

@FierceMedDev: Lineagen reels in $19.8M in Series C round for autism genetic tests. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Vagus nerve stimulation, other forms of bioelectric medicine on cover of Scientific American. Item | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Boston Scientific hands over $600M to settle breach-of-contract Guidant suit with J&J. Article | Follow @EmilyWFierce

> GE recalls 10,000+ MRIs after FDA deems them potentially deadly, citing poor training. News

> Mayo Clinic joins $20.5M Series A reboot for next-gen sequencing startup Lifecode. Story

> FDA panel considering PMA application of spinal implant due to fractures. Article

Biotech News

@FierceBiotech: Lilly delays its high-risk 'good' cholesterol trial with IMPROVE-IT in mind. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Star scientist Peter Mueller gets $28M war chest to advance R&D at Pronutria. Article | Follow @JohnCFierce

@DamianFierce: Someone needs to talk to Mark Levin about this sweater situation. More | Follow @DamianFierce

> Roche and Exelixis roll toward FDA approval with a melanoma cocktail. More

> Kite dives into manufacturing amid CAR-T frenzy. Story

> Novartis leads a $28M round for rare disease biotech Merganser. Article

Vaccines News

> Advaxis nets $23M in financing for cancer vaccine development. More

> Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot. News

> Novavax's Ebola vaccine is in hot pursuit of GSK, Merck, J&J candidates. Story

> VaxInnate reaps $53M for flu jab trials on BARDA contract extension. Article

> Gates Foundation, WHO fund synthetic polio vaccine development. Report

Pharma Manufacturing News

> Taro recalls nearly 37,000 bottles of children's allergy relief syrup. Article

> WuXi inks deal to borrow $165M to support manufacturing growth. News

> InvaGen Pharma and AlphaMed Bottles building new plants on Long Island. Story

> Protein Sciences cancels expansion plans after governor gets flu shot from foreign competitor. Item

> India mulling plans to build bulk drug manufacturing capacity. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.